Boehringer Ingelheim, Survodutide, BI 456906, SYNCHRONIZE-2, Obesity, Type 2 Diabetes, T2D, GLP-1, Glucagon, Dual Agonist, Weight Loss, Glycemic

INGELHEIM, Germany — October 1, 2026 Boehringer Ingelheim announced positive results from the Phase III SYNCHRONIZE-2 trial evaluating survodutide...